Company Coverage
Sino Biopharmaceutical (1177 HK): Innovation Continues To Fuel Growth
BUY (Maintained)
Current price:
Target price:
Upside:
Previous TP :
HK$5.19
HK$7.20
+38.7%
HK$$7.70
Analyst
Analyst
Highlights
- Despite weak generics, Sino Biopharm's innovative drug revenue and out-licensing income will drive double-digit revenue growth in 1H26. 1H26 adjusted net earnings may fluctuate sharply due to the absence of aRmb1.35b special dividend from associate Sinovac LS in 1H25, while we still expect double-digit earnings growth for 2026.
- Backed by new in-licensed products and strong R&D, Sino Biopharm should
see steady revenue and earnings growth in 2027.
- Maintain BUY, with target price trimmed to HK$7.20 on generic drug policy
headwinds.
Analysis
- Licence fee income becomes new growth driver. Sino Biopharmaceutical (Sino Biopharm) has entered into two major out-licensing agreements. The collaboration with Sanofi and AstraZeneca on Rovadicitnib (a potential global first-in-class JAK/ROCK inhibitor) and TQC3721 (PDE3/4 inhibitor) respectively, will bring in a total upfront income of US$335m. According to management, the US$135m was received from Sanofi and will likely be recognised as revenue in 1H26, while approximately 90% of US$200m from AstraZeneca may be recognised at 2H26 revenue based on the progress of the collaborations. The out-licensing income will likely contribute to over 5% of total revenue in 2026.
Highlights
- Despite weak generics, Sino Biopharm's innovative drug revenue and out-licensing income will drive double-digit revenue growth in 1H26. 1H26 adjusted net earnings may fluctuate sharply due to the absence of aRmb1.35b special dividend from associate Sinovac LS in 1H25, while we still expect double-digit earnings growth for 2026.
- Backed by new in-licensed products and strong R&D, Sino Biopharm should
see steady revenue and earnings growth in 2027.
- Maintain BUY, with target price trimmed to HK$7.20 on generic drug policy
headwinds.
Analysis
- Licence fee income becomes new growth driver. Sino Biopharmaceutical (Sino Biopharm) has entered into two major out-licensing agreements. The collaboration with Sanofi and AstraZeneca on Rovadicitnib (a potential global first-in-class JAK/ROCK inhibitor) and TQC3721 (PDE3/4 inhibitor) respectively, will bring in a total upfront income of US$335m. According to management, the US$135m was received from Sanofi and will likely be recognised as revenue in 1H26, while approximately 90% of US$200m from AstraZeneca may be recognised at 2H26 revenue based on the progress of the collaborations. The out-licensing income will likely contribute to over 5% of total revenue in 2026.
BUY (Maintained)
Current price:
Target price:
Upside:
Previous TP :
HK$5.19
HK$7.20
+38.7%
HK$$7.70
Analyst
Analyst
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at the following link: https://research-api.uobkayhian.com/assets/disclaimer/df64a6ea-7980-447c-ae9e-fd19b93257dc, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
